News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Precision Therapeutics, Inc. Release: Two Pivotal Manuscripts On ChemoFx Accepted For Publication



6/26/2014 11:05:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PITTSBURGH--(BUSINESS WIRE)--Precision Therapeutics, Inc. announces that two key manuscripts on the ChemoFx® drug response marker have been accepted for publication. British Journal of Cancer, the elite professional medical journal of Cancer Research UK, has accepted a manuscript detailing the predictive abilities of ChemoFx. In addition, Clinical and Translational Oncology has accepted a manuscript that examines whether access to ChemoFx results has a positive impact on patient outcomes. Together, these key publications will provide further evidence of the clinical utility of the drug response marker as well as answer important clinical questions asked by physicians personalizing patient treatment and payers covering this important test.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES